Cargando…
6-Month Subcutaneous Leuprolide Acetate Effectively Suppresses Clinical Signs of Puberty in Children With Central Precocious Puberty
Objective: Gonadotropin-releasing hormone (GnRH) agonists, such as intramuscular leuprolide acetate, triptorelin and the subcutaneous histrelin implant, are standard treatment for central precocious puberty (CPP). Implants require surgery and sometimes anesthesia, while frequent intramuscular inject...
Autores principales: | Eugster, Erica A, Atkinson, Stuart, Boldt-Houle, Deborah, Miller, Bradley Scott |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8090639/ http://dx.doi.org/10.1210/jendso/bvab048.1356 |
Ejemplares similares
-
THU195 6-Month Subcutaneous Leuprolide Acetate Achieved And Maintained Hormonal And Clinical Suppression In All Weight Groups Of Children With Central Precocious Puberty
por: Miller, Bradley S, et al.
Publicado: (2023) -
ODP397 Small-volume, Subcutaneous, 6-month Leuprolide Acetate Effectively Reduces Growth Velocity to Prepubertal Levels in Children with Central Precocious Puberty
por: Klein, Karen O, et al.
Publicado: (2022) -
Phase 3 Trial of a Small-volume Subcutaneous 6-Month Duration Leuprolide Acetate Treatment for Central Precocious Puberty
por: Klein, Karen O, et al.
Publicado: (2020) -
Pseudotumor cerebri in patient on leuprolide acetate for central precocious puberty
por: Omar, Anjumanara Anver, et al.
Publicado: (2020) -
Leuprolide Acetate 1-Month Depot for Central Precocious Puberty: Hormonal Suppression and Recovery
por: Neely, E. Kirk, et al.
Publicado: (2010)